US6355681B2
(en)
*
|
1995-12-07 |
2002-03-12 |
Glytech, Inc. |
Glycine substitutes and precursors for treating a psychosis
|
US6512010B1
(en)
*
|
1996-07-15 |
2003-01-28 |
Alza Corporation |
Formulations for the administration of fluoxetine
|
US8022095B2
(en)
*
|
1996-08-16 |
2011-09-20 |
Pozen, Inc. |
Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
|
DE1073432T1
(de)
*
|
1998-04-14 |
2002-02-07 |
The General Hospital Corp., Boston |
Verwendung von glycinrezeptoragonisten und glycinaufnahmeinhibitoren zur behandlung neuropsychiatrischer beschwerden
|
AU6472799A
(en)
*
|
1998-10-16 |
2000-05-08 |
Janssen Pharmaceutica N.V. |
Therapy for improving cognition
|
US6337328B1
(en)
*
|
1999-03-01 |
2002-01-08 |
Sepracor, Inc. |
Bupropion metabolites and methods of use
|
DE19918105C1
(de)
*
|
1999-04-22 |
2000-09-21 |
Lohmann Therapie Syst Lts |
Transdermales therapeutisches System mit einem stark wirksamen Neuroleptikum
|
US7146209B2
(en)
*
|
2000-05-08 |
2006-12-05 |
Brainsgate, Ltd. |
Stimulation for treating eye pathologies
|
DK1365787T3
(da)
|
2000-08-25 |
2007-07-23 |
Res Corp Technologies Inc |
Anvendelse af aminosyre-holdige, krampestillende midler til behandling af smerte
|
US20030232890A1
(en)
*
|
2000-11-01 |
2003-12-18 |
Sention, Inc. |
Methods for treating an impairment in memory consolidation
|
US20030119884A1
(en)
*
|
2000-11-01 |
2003-06-26 |
Epstein Mel H. |
Methods and compositions for regulating memory consolidation
|
AU3946402A
(en)
*
|
2000-11-01 |
2002-05-27 |
Sention Inc |
Methods and compositions for regulating memory consolidation
|
US20050059743A1
(en)
*
|
2000-11-01 |
2005-03-17 |
Sention, Inc. |
Methods for treating mild cognitive impairment and alzheimer's disease
|
US7619005B2
(en)
*
|
2000-11-01 |
2009-11-17 |
Cognition Pharmaceuticals Llc |
Methods for treating cognitive impairment in humans with Multiple Sclerosis
|
US20070117869A1
(en)
*
|
2000-11-01 |
2007-05-24 |
Cognition Pharmaceuticals Llc |
Methods for treating coginitive impairment and improving cognition
|
US20020155170A1
(en)
*
|
2000-11-30 |
2002-10-24 |
Walsh William John |
Nutrient supplements and methods for treating autism and for preventing the onset of autism
|
US20030166554A1
(en)
*
|
2001-01-16 |
2003-09-04 |
Genset, S.A. |
Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
|
US20030185754A1
(en)
*
|
2001-01-16 |
2003-10-02 |
Genset, S.A. |
Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
|
CA2442330A1
(en)
|
2001-03-29 |
2002-10-10 |
Emory University |
Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
|
WO2005016319A2
(en)
*
|
2003-08-06 |
2005-02-24 |
Emory University |
Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
|
EP1935414A3
(en)
*
|
2001-05-02 |
2010-08-18 |
Blanchette Rockefeller Neurosciences Institute |
Carbonic anhydrase activators for enhancig learning and memory
|
CA2446074C
(en)
*
|
2001-05-02 |
2011-09-06 |
Blanchette Rockefeller Neurosciences Institute |
Carbonic anhydrase activators for enhancing learning and memory
|
US7766013B2
(en)
|
2001-06-05 |
2010-08-03 |
Alexza Pharmaceuticals, Inc. |
Aerosol generating method and device
|
US20070122353A1
(en)
|
2001-05-24 |
2007-05-31 |
Hale Ron L |
Drug condensation aerosols and kits
|
US7498019B2
(en)
|
2001-05-24 |
2009-03-03 |
Alexza Pharmaceuticals, Inc. |
Delivery of compounds for the treatment of headache through an inhalation route
|
US7645442B2
(en)
|
2001-05-24 |
2010-01-12 |
Alexza Pharmaceuticals, Inc. |
Rapid-heating drug delivery article and method of use
|
US7458374B2
(en)
|
2002-05-13 |
2008-12-02 |
Alexza Pharmaceuticals, Inc. |
Method and apparatus for vaporizing a compound
|
EP1392262A1
(en)
|
2001-05-24 |
2004-03-03 |
Alexza Molecular Delivery Corporation |
Delivery of drug esters through an inhalation route
|
US7005138B2
(en)
*
|
2001-12-21 |
2006-02-28 |
Duramed Pharmaceuticals, Inc. |
Method of systematically delivering SSRIs
|
IL162666A0
(en)
|
2001-12-28 |
2005-11-20 |
Teva Pharma |
A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
|
BE1015608A6
(fr)
*
|
2003-07-15 |
2005-06-07 |
Messadek Jallal |
Traitement des arterites.
|
JPWO2003068215A1
(ja)
*
|
2002-02-14 |
2005-06-02 |
味の素株式会社 |
ミトコンドリア病用薬剤
|
CA2478808A1
(en)
*
|
2002-03-15 |
2003-09-25 |
H. Lundbeck A/S |
Use of asc-1 inhibitors to treat neurological and psychiatric disorders
|
WO2004043218A2
(en)
*
|
2002-11-14 |
2004-05-27 |
Brainsgate Ltd. |
Surgical tools and techniques for stimulation
|
US7684859B2
(en)
*
|
2002-04-25 |
2010-03-23 |
Brainsgate Ltd. |
Stimulation of the OTIC ganglion for treating medical conditions
|
WO2003104811A2
(en)
*
|
2002-06-10 |
2003-12-18 |
Evotec Neurosciences Gmbh |
Diagnostic and therapeutic use of steroidogenic acute regulatory protein for neurodegenerative diseases
|
KR100446503B1
(ko)
*
|
2002-06-19 |
2004-09-04 |
삼성전자주식회사 |
복합 억세스 포인트 장치 및 복합 억세스 포인트 장치를이용한 음성/데이터 패킷 처리 방법
|
US20050164400A1
(en)
*
|
2002-07-04 |
2005-07-28 |
Kenji Hashimoto |
Method of examining and diagnosing integration dysfunction syndrome
|
WO2004010932A2
(en)
*
|
2002-07-30 |
2004-02-05 |
Peter Migaly |
Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
|
FR2843590B1
(fr)
*
|
2002-08-14 |
2007-10-05 |
Prestwick Scient Capital Inc |
Derives de l'acide r(+)-2-amino-3-hydroxypropanoique a action glycinergique
|
US9174975B2
(en)
*
|
2002-08-22 |
2015-11-03 |
Sumitomo Dainippon Pharma Co., Ltd |
Remedy for integration dysfunction syndrome
|
US7160913B2
(en)
*
|
2002-09-13 |
2007-01-09 |
Thomas Jefferson University |
Methods and kit for treating Parkinson's disease
|
US20040067986A1
(en)
*
|
2002-10-04 |
2004-04-08 |
Nathan Sassover |
Neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer
|
US8487002B2
(en)
*
|
2002-10-25 |
2013-07-16 |
Paladin Labs Inc. |
Controlled-release compositions
|
PL377679A1
(pl)
*
|
2002-10-25 |
2006-02-06 |
Pfizer Products Inc. |
Nowe preparaty typu depot do wstrzykiwania
|
TWI319713B
(en)
|
2002-10-25 |
2010-01-21 |
|
Sustained-release tramadol formulations with 24-hour efficacy
|
US20040105818A1
(en)
|
2002-11-26 |
2004-06-03 |
Alexza Molecular Delivery Corporation |
Diuretic aerosols and methods of making and using them
|
US7913688B2
(en)
|
2002-11-27 |
2011-03-29 |
Alexza Pharmaceuticals, Inc. |
Inhalation device for producing a drug aerosol
|
DE60317098T2
(de)
|
2002-12-27 |
2008-08-07 |
Otsuka Pharmaceutical Co., Ltd. |
Carbostyril-derivate mit selektiven serotonin-aufnahmeinhibitoren zur behandlung von gemütskrankheiten
|
AR042806A1
(es)
*
|
2002-12-27 |
2005-07-06 |
Otsuka Pharma Co Ltd |
Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
|
US20070249537A1
(en)
*
|
2003-01-23 |
2007-10-25 |
Supernus Pharmaceuticals, Inc. |
Absorption enhancing agents
|
IL154318A
(en)
|
2003-02-06 |
2010-05-31 |
Sarah Herzog Memorial Hospital |
Pharmaceutical compositions for the treatment of movement disorders
|
ES2278314T3
(es)
*
|
2003-04-17 |
2007-08-01 |
Jallal Messadek |
Formulaciones orales para la liberacion controlada de la betaina.
|
BRPI0410378A
(pt)
*
|
2003-05-16 |
2006-06-13 |
Pfizer Prod Inc |
tratamento de distúrbios psicóticos e depressivos
|
US20050079166A1
(en)
|
2003-05-21 |
2005-04-14 |
Alexza Molecular Delivery Corporation |
Self-contained heating unit and drug-supply unit employing same
|
WO2004112700A2
(en)
*
|
2003-06-06 |
2004-12-29 |
The General Hospital Corporation |
Methods and compositions for modulating amyloid precursor protein translation
|
WO2004113333A1
(ja)
|
2003-06-23 |
2004-12-29 |
Dainippon Sumitomo Pharma Co., Ltd. |
老人性痴呆症治療剤
|
NZ527142A
(en)
*
|
2003-07-23 |
2006-03-31 |
Douglas Pharmaceuticals Ltd |
A stable suspension formulation
|
US7838029B1
(en)
*
|
2003-07-31 |
2010-11-23 |
Watson Laboratories, Inc. |
Mirtazapine solid dosage forms
|
US20060128657A1
(en)
*
|
2003-08-04 |
2006-06-15 |
Jallal Messadek |
Selected betaines and their uses
|
US20060172006A1
(en)
*
|
2003-10-10 |
2006-08-03 |
Vincent Lenaerts |
Sustained-release tramadol formulations with 24-hour clinical efficacy
|
US20050096311A1
(en)
*
|
2003-10-30 |
2005-05-05 |
Cns Response |
Compositions and methods for treatment of nervous system disorders
|
EP1713486A4
(en)
*
|
2003-12-02 |
2009-04-29 |
Sheldon Leslie James |
COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY
|
CN1964713A
(zh)
*
|
2003-12-23 |
2007-05-16 |
达法尔摩公司 |
多巴胺-受体结合化合物的共同使用
|
US20120225916A1
(en)
*
|
2003-12-29 |
2012-09-06 |
Mcdevitt Jason P |
Compositions and Methods to Improve Treatment of Medical Conditions Using D-Cycloserine
|
CA2592631A1
(en)
|
2003-12-29 |
2005-07-21 |
Jason Mcdevitt |
Compositions and methods to treat recurrent medical conditions
|
US20050171088A1
(en)
*
|
2004-01-30 |
2005-08-04 |
Astrazeneca Ab |
Treatment of psychoses with dibenzothiazepine antipsychotic
|
US8055347B2
(en)
|
2005-08-19 |
2011-11-08 |
Brainsgate Ltd. |
Stimulation for treating brain events and other conditions
|
US8010189B2
(en)
*
|
2004-02-20 |
2011-08-30 |
Brainsgate Ltd. |
SPG stimulation for treating complications of subarachnoid hemorrhage
|
US9233245B2
(en)
|
2004-02-20 |
2016-01-12 |
Brainsgate Ltd. |
SPG stimulation
|
US20070160537A1
(en)
|
2004-02-20 |
2007-07-12 |
Takeo Ishiyama |
In vivo screening method of therapeutic agent for memory/learning dysfunctions by schizophrenia
|
US7262318B2
(en)
*
|
2004-03-10 |
2007-08-28 |
Pfizer, Inc. |
Substituted heteroaryl- and phenylsulfamoyl compounds
|
CA2609972C
(en)
*
|
2004-03-22 |
2013-05-14 |
Apkarian Technologies Llc |
Method and compositions for treatment of chronic neuropathic pain
|
TW201207390A
(en)
|
2004-05-18 |
2012-02-16 |
Brni Neurosciences Inst |
Method for screening agent for antidepressant activity
|
US20050261278A1
(en)
|
2004-05-21 |
2005-11-24 |
Weiner David M |
Selective serotonin receptor inverse agonists as therapeutics for disease
|
US20050277626A1
(en)
*
|
2004-05-27 |
2005-12-15 |
Neurocure Ltd. |
Methods and compositions for treatment of nicotine dependence and dementias
|
US7540286B2
(en)
|
2004-06-03 |
2009-06-02 |
Alexza Pharmaceuticals, Inc. |
Multiple dose condensation aerosol devices and methods of forming condensation aerosols
|
EP1604656A1
(en)
|
2004-06-09 |
2005-12-14 |
Schwarz Pharma Ag |
Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
|
CA2601716C
(en)
*
|
2004-06-25 |
2011-05-31 |
Board Of Regents, The University Of Texas System |
Methods and compositions for the treatment of attention deficit hyperactivity disorder and hyperphenylalanemia
|
US20050288340A1
(en)
*
|
2004-06-29 |
2005-12-29 |
Pfizer Inc |
Substituted heteroaryl- and phenylsulfamoyl compounds
|
US20060039866A1
(en)
*
|
2004-08-20 |
2006-02-23 |
Cypress Bioscience, Inc. |
Method for treating sleep-related breathing disorders
|
WO2006021957A2
(en)
*
|
2004-08-23 |
2006-03-02 |
Brainsgate Ltd. |
Concurrent bilateral spg modulation
|
WO2006034196A1
(en)
*
|
2004-09-17 |
2006-03-30 |
Lifelike Biomatic Inc. |
Compositions for enhancing memory and methods therefor
|
WO2006050581A2
(en)
*
|
2004-11-10 |
2006-05-18 |
Jallal Messadek |
Betaine as agent against arthropod - or mosquito -borne diseases
|
US20060122127A1
(en)
*
|
2004-11-17 |
2006-06-08 |
Cypress Bioscience, Inc. |
Methods for reducing the side effects associated with mirtzapine treatment
|
WO2006060186A2
(en)
*
|
2004-11-30 |
2006-06-08 |
Bayer Pharmaceuticals Corporation |
Pyrazole derivatives for the treatment of dementia and related disorders
|
US20060154919A1
(en)
*
|
2004-12-16 |
2006-07-13 |
Moyer John A |
Combination of a glycine transporter (GLYT1) inhibitor and an antipsychotic for the treatment of symptoms of schizophrenia as well as its preparation and use thereof
|
ATE476431T1
(de)
*
|
2004-12-21 |
2010-08-15 |
Merck Sharp & Dohme |
Piperidin- und azetidinderivate als glyt1- inhibitoren
|
WO2006134341A1
(en)
*
|
2005-06-13 |
2006-12-21 |
Merck Sharp & Dohme Limited |
Therapeutic agents
|
CA2615147A1
(en)
*
|
2005-07-14 |
2007-01-18 |
The University Of British Columbia |
Neuroprotective modulation of nmda receptor subtype activities
|
BRPI0615860B8
(pt)
*
|
2005-09-09 |
2021-05-25 |
Labopharm Barbados Ltd |
composição farmacêutica de liberação prolongada monolítica sólida
|
ATE549921T1
(de)
|
2005-09-29 |
2012-04-15 |
Merck Sharp & Dohme |
Radioaktiv markierte glycintransporter-hemmer
|
WO2007111982A2
(en)
*
|
2006-03-24 |
2007-10-04 |
Wyeth |
Methods for treating cognitive and other disorders
|
US7884124B2
(en)
|
2006-06-30 |
2011-02-08 |
Sepracor Inc. |
Fluoro-substituted inhibitors of D-amino acid oxidase
|
US7531572B2
(en)
*
|
2006-07-28 |
2009-05-12 |
Xenoport, Inc. |
Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use
|
US20090210026A1
(en)
*
|
2006-08-17 |
2009-08-20 |
Brainsgate Ltd. |
Spg stimulation for enhancing neurogenesis and brain metabolism
|
US20080081067A1
(en)
*
|
2006-10-03 |
2008-04-03 |
Gupta Manishkumar |
Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
|
CA2664366C
(en)
*
|
2006-11-09 |
2018-09-04 |
Centre For Addiction And Mental Health |
Slc1a1 antipsychotic drug response markers
|
EP2121088B1
(en)
|
2007-03-09 |
2016-07-13 |
Alexza Pharmaceuticals, Inc. |
Heating unit for use in a drug delivery device
|
WO2008118785A2
(en)
*
|
2007-03-23 |
2008-10-02 |
Tikvah Therapeutics |
Methods for treating depression using immediate-impact treatments and d-cycloserine
|
US20100113453A1
(en)
*
|
2007-04-10 |
2010-05-06 |
Mcdevitt Jason P |
Sublingual Formulations of D-Cycloserine and Methods of Using Same
|
WO2008128166A1
(en)
*
|
2007-04-13 |
2008-10-23 |
Concert Pharmaceuticals Inc. |
Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds
|
WO2008157094A1
(en)
*
|
2007-06-13 |
2008-12-24 |
Cypress Bioscience, Inc. |
Improving the tolerability of mirtazapine and a second active by using them in combination
|
US8580776B2
(en)
*
|
2007-07-10 |
2013-11-12 |
The Board Of Trustees Of The University Of Illinois |
Compositions and methods for treating neurodegenerating diseases
|
WO2009018368A1
(en)
*
|
2007-07-30 |
2009-02-05 |
Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center |
Combination treatment of nmda (n-methyl-d-aspartate)-enhancer, glycine transporter inhibitor, d-amino acid oxidase inhibitor (daaoi) for neuropsychiatric disorders
|
US7860569B2
(en)
|
2007-10-18 |
2010-12-28 |
Brainsgate, Ltd. |
Long-term SPG stimulation therapy for prevention of vascular dementia
|
WO2009065193A1
(en)
*
|
2007-11-21 |
2009-05-28 |
Jallal Messadek |
Treatment of aspirin resistance with betaine and/or betaine enriched molasses
|
IL188681A0
(en)
*
|
2008-01-09 |
2008-12-29 |
Amino Acid Solutions Inc |
Pharmaceutical compositions and methods utilizing a d-amino acid
|
EP2111858A1
(en)
*
|
2008-04-25 |
2009-10-28 |
EPFL Ecole Polytechnique Fédérale de Lausanne |
Novel treatment for alzheimer's disease
|
GB0817379D0
(en)
*
|
2008-09-23 |
2008-10-29 |
Merck Sharp & Dohme |
New use
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
US20110237537A1
(en)
*
|
2009-05-29 |
2011-09-29 |
Lombard Jay L |
Methods for assessment and treatment of mood disorders via single nucleotide polymorphisms analysis
|
US20120041066A1
(en)
*
|
2010-08-16 |
2012-02-16 |
Lombard Jay L |
Medical foods for the treatment of developmentally-based neuropsychiatric disorders via modulation of brain glycine and glutathione pathways
|
US8355927B2
(en)
|
2010-11-05 |
2013-01-15 |
Genomind, Llc |
Neuropsychiatric test reports
|
BR112012008146A2
(pt)
*
|
2009-09-14 |
2019-09-24 |
Shiseido Co Ltd |
composição para alívio dos danos causados por meio da irradiação ultravioleta
|
TWI544923B
(zh)
*
|
2009-12-29 |
2016-08-11 |
何應瑞 |
用於治療神經退化性疾病之醫藥組合物
|
EP2538939A1
(en)
*
|
2010-02-24 |
2013-01-02 |
Universität Zürich |
Prevention and treatment of diseases caused by elevated levels of deoxy-sphingolipids
|
US8258139B2
(en)
|
2010-11-08 |
2012-09-04 |
Dainippon Sumitomo Pharma Co., Ltd. |
Method of treatment for mental disorders
|
EP2638005A4
(en)
*
|
2010-11-12 |
2015-04-01 |
Promentis Pharm Inc |
S-T-BUTYL-CYSTONE-PROTECTED DI-PEPTIDE ANALOGS AND ASSOCIATED COMPOUNDS
|
US10583138B2
(en)
|
2012-07-12 |
2020-03-10 |
Glytech, Llc |
Composition and method for treatment of depression and psychosis in humans
|
ES2673956T3
(es)
|
2011-01-31 |
2018-06-26 |
Serotech, Llc |
Régimen de dosificación, envase de dispensación de la medicación y usos de los mismos para el tratamiento del trastorno depresivo mayor
|
US9737531B2
(en)
|
2012-07-12 |
2017-08-22 |
Glytech, Llc |
Composition and method for treatment of depression and psychosis in humans
|
JP6265908B2
(ja)
|
2011-11-21 |
2018-01-24 |
ザ インスティチュート フォー エスノメディシン |
神経変性疾患および障害を処置するためのl−セリン組成物、方法および使用
|
US20130296430A1
(en)
*
|
2012-05-03 |
2013-11-07 |
Antonio Hardan |
Compositions and methods for treating autism and autism spectrum disorder
|
KR101499299B1
(ko)
*
|
2012-08-03 |
2015-03-09 |
연세대학교 산학협력단 |
Shank2 유전자가 결실된 자폐증 모델 형질전환마우스 및 그 용도
|
US20150209306A1
(en)
*
|
2012-08-07 |
2015-07-30 |
Buck Institute For Research On Aging |
Multi-component formulation for improving neurological function
|
US9265458B2
(en)
|
2012-12-04 |
2016-02-23 |
Sync-Think, Inc. |
Application of smooth pursuit cognitive testing paradigms to clinical drug development
|
US9380976B2
(en)
|
2013-03-11 |
2016-07-05 |
Sync-Think, Inc. |
Optical neuroinformatics
|
AT514349B1
(de)
*
|
2013-06-12 |
2018-05-15 |
Red Bull Gmbh |
Alpha-alkylierte Aminosäuren (AAAAs)
|
US20160206583A1
(en)
*
|
2013-08-27 |
2016-07-21 |
The Johns Hopkins University |
Amino acid treatment of seizures
|
US9675796B2
(en)
|
2013-11-10 |
2017-06-13 |
Brainsgate Ltd. |
Implant and delivery system for neural stimulator
|
US9877951B2
(en)
|
2015-02-12 |
2018-01-30 |
College Of William And Mary |
Method for treating dementia
|
WO2016132136A1
(en)
|
2015-02-18 |
2016-08-25 |
Aston University |
Diagnostic assay and treatment for preeclampsia
|
US10709668B2
(en)
|
2015-05-04 |
2020-07-14 |
Confluence Pharmaceuticals, Llc |
Sprinkle formulations of acamprosate
|
EP3093043B1
(en)
|
2015-05-13 |
2018-11-14 |
Brainsgate Ltd. |
Implant and delivery system for neural stimulator
|
CA2993614A1
(en)
*
|
2015-08-04 |
2017-02-09 |
Confluence Pharmaceuticals, Llc |
Combination therapy using acamprosate and d-cycloserine
|
US20170143681A1
(en)
|
2015-11-02 |
2017-05-25 |
Apkarian Technologies Llc |
Methods and compositions for treating pain
|
CN105476976B
(zh)
*
|
2015-12-22 |
2018-09-25 |
广州瑞尔医药科技有限公司 |
药物组合物及其制备方法和应用
|
TWI648049B
(zh)
*
|
2016-05-25 |
2019-01-21 |
National Health Research Institutes |
用於減低k他命之致精神病狀副作用及成癮疾患的方法與組成物
|
US9877942B1
(en)
*
|
2017-02-13 |
2018-01-30 |
Syneurx International (Taiwan) Corp. |
Co-crystals of substituted glycine and uses thereof
|
JP2020519669A
(ja)
|
2017-05-17 |
2020-07-02 |
コンフルーエンス ファーマシューティカルズ,エルエルシー |
ホモタウリンおよびその塩の製剤
|
WO2018216020A1
(en)
*
|
2017-05-25 |
2018-11-29 |
Glytech Llc. |
Combined therapy for nmdar antagonist-responsive neuropsychiatric disorders
|
US10226442B2
(en)
*
|
2017-07-10 |
2019-03-12 |
Syneurx International (Taiwan) Corp. |
Lithium salts of N-substituted glycine compounds and uses thereof
|
CA3082834A1
(en)
*
|
2017-11-22 |
2019-05-31 |
Concert Pharmaceuticals, Inc. |
Deuterated analogs of d-serine and uses thereof
|
KR101952443B1
(ko)
*
|
2018-08-23 |
2019-02-26 |
주식회사 아스트로젠 |
신규한 마그네슘세리네이트 화합물 및 이의 용도
|
JP2023549174A
(ja)
*
|
2020-11-04 |
2023-11-22 |
グリアセルテック・インコーポレイテッド |
クロルプロマジンを含む神経炎症性疾患の予防または治療用組成物
|
WO2023171106A1
(ja)
*
|
2022-03-08 |
2023-09-14 |
ソシウム株式会社 |
Tdp-43の凝集の抑制剤、tdp-43が過剰発現している細胞の細胞死の抑制剤、及びtdp-43の凝集を伴う疾患の治療又は予防剤
|